Advanced Search

 

Study ID Status Title Patient Level Data
EGF101950 Withdrawn Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib
EGF102580 Completed A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Lapatinib in Combination with Paclitaxel as Neoadjuvant Therapy in Patients with Newly Diagnosed Inflammatory Breast Cancer
EGF102980 Completed A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients with Relapsed Adenocarcinoma of the Esophagus, including Tumors of the Gastroesophageal Junction and Gastric Cardia
EGF102988 Completed A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
EGF103009 Completed A Phase II Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Lapatinib in Patients with Relapsed or Refractory Inflammatory Breast Cancer
EGF103659 Active, Not Recruiting An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
EGF103890 Active, Not Recruiting A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination with Bevacizumab in Subjects with Advanced or Metastatic ErbB2-Overexpressing Breast Cancer
EGF103892 Active, Not Recruiting A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination with Carboplatin, Paclitaxel, and Herceptin in Patients with Metastatic Breast Cancer
EGF104334 Completed A Randomized, Single Blinded, Placebo-controlled, Multi-centre, Phase II Study of Lapatinib in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
EGF104383 Active, Not Recruiting A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing the Activity of Paclitaxel Plus Trastuzumab Plus Lapatinib to Paclitaxel Plus Trastuzumab Plus Placebo in Women with ErbB2 Overexpressing Metastatic Breast Cancer
EGF104535 Active, Not Recruiting A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination with Paclitaxel versus Paclitaxel plus Placebo in Subjects with ErbB2 Amplified Metastatic Breast Cancer
EGF104900 Completed A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination with Trastuzumab versus Lapatinib Monotherapy in Subjects with HER2-positive Metastatic Breast Cancer whose disease has progressed on Trastuzumab-Containing Regimens
EGF104911 Completed Phase II Clinical Study of lapatinib (GW572016) in Patients with ErbB2 Over - Expressing Advanced or Metastatic Breast Cancer
EGF105084 Active, Not Recruiting A Phase II Study of Lapatinib for Brain Metastases in Subjects with ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
EGF105485 Completed A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib (GW572016) in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
EGF105635 Completed Phase I/II Clinical Study of GW572016 (Lapatinib Ditosylate Monohydrate) in Combination with Trastuzumab in Patients with Breast Cancer Previously Treated with Trastuzumab
EGF105764 Completed An open-label, single-arm, multi-centre, Phase II study of oral lapatinib in combination with paclitaxel as first-line treatment for ErbB2-amplified metastatic breast cancer patients
EGF105884 Completed A Randomized, double-blind, placebo controlled, multicentre, phase II study of oral lapatinib in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in subjects with stage III, IVA, B squamous cell carcinoma of the head and neck (SCCHN)
EGF106708 Active, Not Recruiting A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
EGF106903 Active, Not Recruiting Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study: A randomised, multicenter open-label phase III study of neoadjuvant lapatinib, trastuzumab and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer
EGF106988 Completed Chemotherapy plus lapatinib or trastuzumab or both in Her2+ primary breast cancer. A randomized phase IIb study with biomarker evaluation.
EGF107692 Completed Letrozole versus Letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER-2 negative operable breast cancer. A double blind randomized Phase II study with biomarker evaluation.
EGF108916 Terminated An open-label, multi-centre study of lapatinib in combination with chemotherapy in patients with ErbB2 over expressing breast cancer after trastuzumab failure in the neoadjuvant or adjuvant setting
EGF108991 Completed A Phase I/II Study of Lapatinib in Combination with Oxaliplatin and Capecitabine in Subjects with Advanced or Metastatic Colorectal Cancer
EGF109462 Completed A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.